Mogrify Raises $17 Million to Advance Reprogrammed Cell Therapies
Share
U.K. biotech Mogrify, which is focused on novel cell-based and
in vivo reprogramming for novel therapeutic applications, raised $17 million to close a series A financing round totaling $33 million.
Parkwalk Advisors led the second close with additional funding from Astellas Venture Management, 24Haymarket, co-founder of Abcam, Jonathan Milner, and Mogrify CEO Darrin Disley.
Mogrify aims to transform the development of
ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies. Proceeds from the financing will be used to advance Mogrify’s immuno-oncology and ophthalmology programs, inclusive of iPSC-derived allogeneic cell therapies targeting hematological and solid malignancies, as well as